Henry Ford Hospital Medical Journal
Volume 37

Number 1

Article 9

3-1989

Primary Fibrinolysis in Acute Monocytic Leukemia
Ellis J. Van Slyck
Sundara B. K. Raman
Nalini Janakiraman

Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal
Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons

Recommended Citation
Van Slyck, Ellis J.; Raman, Sundara B. K.; and Janakiraman, Nalini (1989) "Primary Fibrinolysis in Acute
Monocytic Leukemia," Henry Ford Hospital Medical Journal : Vol. 37 : No. 1 , 33-36.
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol37/iss1/9

This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has
been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health
System Scholarly Commons.

Case Reports

Primary Fibrinolysis in Acute Monocytic Leukemia
Ellis J. Van Slyck, MD,* Sundara B.K. Raman, MD,t and Nalini Janakiraman, MD*

We present the case of a young man with acute monocytic leukemia
(French-American-British
classification:M5) and systemic hy perfibrinoly sis with severe bleeding. Although fibrinolysis is
usually mild and secorulary to disseminated intravascular coagulation, its role as a primary and
domiruintfactor in rare cases of leukemia warrants that its presence be sought as a cause of abnormal
bleeding. Decreased serum plasminogen and increased serum plasmin determined by synthetic
substrate assay and a negative protamine paracoagulation test are crucial findings. Use of high-dose
epsilon-aminocaproic acid was effective in treating this complication. A transient increase in
fibrinolytic activity coincident with the early effect of antileukemic treatment suggested that
plasminogen activator and/or fibrinolytic protease substances were released from leukemic cells.
Fibrinolytic activity subsequently disappeared with reduction in the population of leukemic cells.
(Henry Ford Hosp MedJ 1989;37:33-6)

A

lthough thrombocytopenia is the abnormality associated
with clinical bleeding in the majority of patients with acute
leukemia (1), other disorders of coagulation are the principal
culprits in some cases (2-6). The frequency of disseminated intravascular coagulation (DIC) in acute promyelocytic leukemia
(French-American-British [FAB] classification:M3) is so well
known that most clinicians treat patients thus afflicted with prophylactic heparin before initiating antileukemic chemotherapy
(7-9). In a smaller number of cases of acute nonlymphocytic leukemia of all FAB types, the presence of DIC with or without
secondary fibrinolysis has been described (10-15). Instances of
apparent primary fibrinolysis, though rare, have been reported
(16-19), although never previously in acute monocytic leukemia
(FAB:M5). We report such a case and note some important diagnostic and therapeutic considerations.

Case Report
A 30-year-old carpenter came to the Emergency Room of Henry Ford
Hospital on June 2, 1980, with atypical substernal pain. He was admitted with a possible myocardial infarction. Physical examination disclosed no abnormalities. The following day the substernal pain spontaneously disappeared, and subsequent studies failed to implicate any
cardiac disease. However, WBC count was noted to be 13.2 x lO'/L
(13,200/|xL) with 0.17 (17%) polys, 0.38 (38%) lymphocytes, 0.05
(5%) monocytes, 0.05 (5%) metamyelocytes, 0.23 (23%) myelocytes,
0.02 (2%) promyelocytes, and 0.10 (10%) blasts. The hemoglobin was
144 g/L (14.4 g%), hematocrit 0.42 (42 vol%), and the platelet count 161
X 10''/L(161,000/fji,L).
A bone marrow examinafion showed overall cellularity of 90% with a
myeloid-to-erythroid ratio of 10:1. It was infiltrated by sheets of blasts
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which were large with sizable spongy nuclei and multiple nucleoli (Fig
1). The cytoplasm of the blasts was abundant, blue, and occasionally
vacuolated. Granulocytes were noted to be hypogranular. Special stains
showed a strongly positive reaction to nonspecific esterase in most of
the blasts. The Sudan Black B, specific esterase, periodic acid-Schiff,
and toluidine blue stains showed nongranulocytic and nonlymphocytic
reaction pattems. A diagnosis of acute monocytic leukemia (FAB:M5)
was made. The patient was treated with doxombicin 60 mg/M^, vincristine 2 mg, cytosine arabinoside 200 mg/M- days 1-7, and prednisone 100 mg days 1-5 (ADOAP). Bone marrow examination on the
eighth day showed 15% cellularity with no blasts present. On July 3rd,
he had recovered from this induction course; his marrow was 70% cellular and in complete remission. The patient then received three courses
of consolidation treatment with ADOAP followed by monthly maintenance with vincristine, cytosine arabinoside, and prednisone. He remained in remission through March 4, 1981 (eight months).
On April 22, 1981, the patient retumed with gross hematuria of two
days' duration. He had also recently noted bmises on the anterior thighs
and had experienced epistaxis and bleeding gums. The physical examination confirmed abnormal bruising. The urine was grossly bloody.
Laboratory studies showed a hemoglobin of 162 g/L (16.2 g%), WBC
count of 24 X lO'/L (24,000/jiL) with 0.12 (12%) blasts. The platelet
count was 192 X lOVL (192,000/|JLL). Bone marrow examination
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Fig 1—Bone marrow aspirate smear showing sheets of large
blasts with abundant cytoplasm and sizable spongy nucleii containing several nucleoli (Leishman stain, XIOOO).

Fig 2—All leukemic blasts in this field show strong nonspecific
positivity (alphanaphthol butyrate esterase, XIOOO).

showed marked hypercellularity with 0.892 (89.2%) large primitive
stem cells. These cells again showed 94% positivity with nonspecific
esterase stain and were diagnostic of acute monocytic leukemia
(FAB:M5) in relapse (Fig 2).
The results ofthe coagulation investigation were as follows: activated
partial thromboplastin time (APTT), done by modification of the
method of Proctor and Rapaport (20) using automated APTT reagent
(activator micronized silica) from General Diagnostics, was significantly prolonged. One stage prothrombin time (PT) done by the method
of Quick (21) using Ortho Brain Thromboplastin was also prolonged.
Fibrinogen measured on Lancerfibrinogenanalyzer using the Lancer
fibrinogen determination reagent kit was 0.4 g/L (40 mg%) (normal 1.8
to 4.1 g/L). Fibrin split products were measured by agglutination of
latex particles. Initial level was 80 jxg/mL (normal < 10 |J.g/mL) and
later increased to 160 \xg/mL. Factor VIII assayed by modified one
stage APTT using the method of Egeberg (22) was increased to over
200% (normal 50% to 150%), and Factor V detennined by the method
of Stefanini (23) was slightly below normal (47%), as was Factor VII
(47%), measured by the method of Owren and Aas (24). Protamine sulfate paracoagulation test (25) was consistendy negative for fibrin monomers suggesting that fibrinolysis was the dominant pathologic process.
Plasminogen and plasmin were assayed by using a synthetic fluorogenic substrate, D-valine-lysine-5-amidoisophthalic acid by the
method of Pochron et al (26) using afluorogenicassay (Protopath™,
Dade Corporation, Miami, FL). The plasminogen level was consistently decreased, reaching levels below 1 CTAU (Committee on Thrombolytic Agents units)/mL (normal 3.1 ± 0 . 7 CTAU/mL). Plasmin was
demonstrated in the serum before epsilon-aminocaproic acid was
given, but subsequent tests were negative.
These data were interpreted as indicating the presence of primary
fibrinolysis. On April 24th, epsilon-aminocaproic acid was begun initially at an oral dose of 5 g every four hours; this was subsequentiy
changed to 1 g every hour intravenously After 48 hours no new areas of
ecchymosis were seen, and by 72 hours the hematuria was greatly improved. On this date (April 27th), antileukemic treatment with ADOAP
was reinstituted, and the epsilon-aminocaproic acid was continued. An
exacerbation in fibrinolysis occurred shortly after chemotherapy was
started, but then strikingly improved and disappeared over the next
seven days. Because of the continued presence of leukemic cells in the

marrow, cytosine arabinoside was administered for an additional three
days. On May 9th, 13 days after reinduction chemotherapy, the patient
had recurrent hematuria and gum bleeding, but this was now thought to
be due to thrombocytopenia since the fibrinolytic parameters were normal. Control of bleeding occurred after the patient received 10 units of
random donor platelets. Epsilon-aminocaproic acid was stopped on
May Uth, and the patient was discharged two days later, having completed chemotherapy and now in a clinically stable state.
However, at home the patient began vomiting with hematemesis. He
arrived in the Emergency Room in shock on May 14th. He was in severe
respiratory distress, having aspirated vomitus. His coagulation parameters now indicated the presence of DIC. Despite intensive supportive
measures, the patient died five hours later The pertinent relationships
between chemotherapy, fibrinolytic therapy, and laboratory values during the clinical course of this patient are depicted in Fig 3.
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Discussion
Fibrinolysis as a primary factor causing significant bleeding
in leukemia is controversial. It is usually thought to be a secondary response to D I C , but, with the use of techniques for the
measurement of plasminogen and plasmin, its occurrence as a
primary phenomenon in leukemia has been observed (18,19).
Fibrinolytic activity derived from the proteases, elastase and
cathepsin G, and from plasminogen activators have been recovered from disrupted normal and leukemic granulocytes and
monocytes (27-29). A case of acute myelomonocyfic leukemia
(FAB:M4) with symptomatic fibrinolysis has been reported, in
which a protease with fibrinolytic activity and a plasminogen activator were demonstrated in the serum (18). Chan et al (19) described two patients with promyelocytic leukemia, in whom low
plasminogen and alpha-2-plasmin inhibitor levels were associated with severe bleeding and in whom transexamic acid, a potent analog of epsilon-aminocaproic acid available in Europe
(30), was therapeutically effective. Schwartz et al (16) claim a
predictive value in finding less than 30% levels of serum al-
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pha-2-plasmin inhibitor in patients with promyelocytic leukemia. Such patients showed evidence of increased fibrinolysis
and responded to aminocaproic acid treatment, but they also received heparin because of evidence of DIC.
Our case represents the apparent rarity of pure monocytic leukemia associated with severefibrinolysis,manifested clinically
by severe bleeding. Decreasedfibrinogenand plasminogen with
elevated fibrin split products, a persistently negative protamine
sulfate paracoagulation test, and a normal platelet count prior to
chemotherapy strongly suggest the presence of marked (probably primary) fibrinolysis. The favorable, although gradual,
response to aminocaproic acid gives further support to this
impression. There is also indirect evidence to implicate the
leukemic cell as the source of fibrinolytic activity, since progressive hemostatic improvement paralleled the reduction in
leukemic cell population induced by chemotherapy. Transient
worsening of the bleeding diathesis at the onset of chemotherapy
was likely due to the greater release of fibrinolytic activators by
the initial disruption of leukemic cells. After resolution of the
hemostatic defect, as shown by the patient's clinical stability
and the normalization of his coagulation parameters, the subsequent terminal bleeding episode was related to sepsis and shock
which produced the not unexpected DIC. This was confirmed by
a strongly positive protamine sulfate paracoagulation test and by
other abnormalities indicating excessive consumption, ie, decreased Factors V and VIII. At autopsy tbe presence of small
fresh fibrin thrombi in several pulmonary and a few renal capillaries gave further evidence of late-occurring DIC.
Regarding treatment of the fibrinolytic episode, we found epsilon-aminocaproic acid to be effective, but prolonged and high
dose (24 g/day intravenously) was necessary. Replacement of
fibrinogen through transfusions of cryoprecipitate was additionally helpful.
Because it is certainly an uncommon clinical problem in the
course of acute leukemia, the presence of fibrinolysis could
go unrecognized, overshadowed by the ubiquitous thrombocytopenia, or mistaken for DIC. We wish to draw attention to
this possibility, since therapeutic options are critical; and we
stress the value of the protamine sulfate paracoagulation test and
the measurement of the serum plasminogen in the evaluation of
the bleeding leukemic patient.
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Fig 3—Relationship between chemotherapy, fibrinolytic therapy, and laboratory values during the clinical course.
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